홈 › 비소세포폐암 › 캘리포니아 › Fullerton
CA Fullerton의 비소세포폐암 임상 시험
비소세포폐암 관련 연구 13개가 Fullerton 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
피험자 모집 중1/2상
- Providence - St. Jude Medical Center /ID# 271414, Fullerton
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
피험자 모집 중3상
- Providence St. Jude Medical Center ( Site 0106), Fullerton
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
피험자 모집 중3상
- Providence Medical Foundation, Fullerton
- Providence St. Jude Medical Center, Fullerton
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
피험자 모집 중2상
- Providence Medical Foundation, Fullerton
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
피험자 모집 중3상
- Providence Medical Foundation, Fullerton
- Providence St. Jude Medical Center Virginia K. Crosson Cancer Center and Infusion Center, Fullerton
- Providence St. Jude Medical Center, Fullerton
- 외 1개
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
피험자 모집 중1/2상
- Providence Medical Foundation, Fullerton
- Providence St. Jude Medical Center - Virginia K. Crosson Cancer Center and Infusion Center, Fullerton
- Providence St. Jude Medical Center, Fullerton
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
피험자 모집 중1상
- Providence Medical Foundation - Fullerton - Virginia K. Crosson Cancer Center, Fullerton
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
피험자 모집 중3상
- Providence Medical Foundation, Fullerton
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
피험자 모집 중3상
- St. Jude Medical Center, Fullerton
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
피험자 모집 중1/2상
- Providence Medical Foundation, Fullerton
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
피험자 모집 중1상
- Providence Medical Foundation, Fullerton
- Providence St. Jude Medical Center Virginia K Crosson and Infusion Center, Fullerton
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
피험자 모집 중3상
- St. Jude Herritage Medical Group, Fullerton
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
피험자 모집 중
- St Jude Heritage Medical Group, Fullerton
다른 도시의 비소세포폐암 시험
- Houston, TX연구 145개
- New York City, NY연구 121개
- Arlington, VA연구 104개
- Nashville, TN연구 97개
- Boston, MA연구 90개
- Los Angeles, CA연구 87개
- St. Louis, MO연구 73개
- Chicago, IL연구 61개
- Baltimore, MD연구 60개
- San Antonio, TX연구 59개
- Columbus, OH연구 57개
- Washington, DC연구 55개
Fullerton의 다른 연구
- 유방암연구 9개
- 난소암연구 6개
- 루푸스연구 5개
- 암 (전체)연구 5개
- 폐암연구 4개
- 췌장암연구 4개
- 위암연구 3개
- 식도암연구 3개
- 흑색종연구 3개
- 두경부 편평세포암연구 3개
- 조현병연구 3개
- 대장직장암연구 3개
ClinicalTrials.gov 출처, 2026. 10. 6. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.